The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary

Marko M. Altaras, Gary L. Goldberg, Wilfred Levin, Lynne Darge, Basil Bloch, James A. Smith

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The value of cancer antigen-125 (CA-125) as a tumor marker for malignant germ cell tumors (MGCT) of the ovary was investigated and compared with the other recognized tumor markers (human chorionic gonadotrophin (hCG), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA)) and lactate dehydrogenase (LDH) isoenzymes. In the 10 months following June 1984, 4 new cases with MGCT and 1 patient with active disease on treatment were evaluated. In all cases prior to planned surgery the levels of CA-125 were significantly elevated. The serum values ranged from 154 to 617 U/ml (normal < 20 U/ml). In 1 case (pure dysgerminoma) CA-125 was the only tumor marker. In 3 patients (2 mixed germ cell tumors and 1 immature teratoma) serum LDH (LD 1, 2, and 3) was elevated, and AFP was elevated in 1 of these. In the fifth case (mixed germ cell tumor), on treatment, serum AFP was used to monitor the disease. Four patients underwent cytoreductive surgery followed by combination chemotherapy. The changes in the serum levels of CA-125 paralleled those of the other tumor markers while on therapy. In our experience CA-125 is an invaluable indicator of the clinical status of the patient and could be a new tumor marker in patients with MGCT.

Original languageEnglish (US)
Pages (from-to)150-159
Number of pages10
JournalGynecologic Oncology
Volume25
Issue number2
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Tumor Biomarkers
Ovary
alpha-Fetoproteins
Antigens
Neoplasms
Serum
Dysgerminoma
Carcinoembryonic Antigen
Teratoma
Chorionic Gonadotropin
Combination Drug Therapy
L-Lactate Dehydrogenase
Isoenzymes
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Altaras, M. M., Goldberg, G. L., Levin, W., Darge, L., Bloch, B., & Smith, J. A. (1986). The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary. Gynecologic Oncology, 25(2), 150-159. https://doi.org/10.1016/0090-8258(86)90096-X

The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary. / Altaras, Marko M.; Goldberg, Gary L.; Levin, Wilfred; Darge, Lynne; Bloch, Basil; Smith, James A.

In: Gynecologic Oncology, Vol. 25, No. 2, 1986, p. 150-159.

Research output: Contribution to journalArticle

Altaras, MM, Goldberg, GL, Levin, W, Darge, L, Bloch, B & Smith, JA 1986, 'The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary', Gynecologic Oncology, vol. 25, no. 2, pp. 150-159. https://doi.org/10.1016/0090-8258(86)90096-X
Altaras, Marko M. ; Goldberg, Gary L. ; Levin, Wilfred ; Darge, Lynne ; Bloch, Basil ; Smith, James A. / The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary. In: Gynecologic Oncology. 1986 ; Vol. 25, No. 2. pp. 150-159.
@article{6438258d800f4668815d5f5daa676740,
title = "The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary",
abstract = "The value of cancer antigen-125 (CA-125) as a tumor marker for malignant germ cell tumors (MGCT) of the ovary was investigated and compared with the other recognized tumor markers (human chorionic gonadotrophin (hCG), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA)) and lactate dehydrogenase (LDH) isoenzymes. In the 10 months following June 1984, 4 new cases with MGCT and 1 patient with active disease on treatment were evaluated. In all cases prior to planned surgery the levels of CA-125 were significantly elevated. The serum values ranged from 154 to 617 U/ml (normal < 20 U/ml). In 1 case (pure dysgerminoma) CA-125 was the only tumor marker. In 3 patients (2 mixed germ cell tumors and 1 immature teratoma) serum LDH (LD 1, 2, and 3) was elevated, and AFP was elevated in 1 of these. In the fifth case (mixed germ cell tumor), on treatment, serum AFP was used to monitor the disease. Four patients underwent cytoreductive surgery followed by combination chemotherapy. The changes in the serum levels of CA-125 paralleled those of the other tumor markers while on therapy. In our experience CA-125 is an invaluable indicator of the clinical status of the patient and could be a new tumor marker in patients with MGCT.",
author = "Altaras, {Marko M.} and Goldberg, {Gary L.} and Wilfred Levin and Lynne Darge and Basil Bloch and Smith, {James A.}",
year = "1986",
doi = "10.1016/0090-8258(86)90096-X",
language = "English (US)",
volume = "25",
pages = "150--159",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary

AU - Altaras, Marko M.

AU - Goldberg, Gary L.

AU - Levin, Wilfred

AU - Darge, Lynne

AU - Bloch, Basil

AU - Smith, James A.

PY - 1986

Y1 - 1986

N2 - The value of cancer antigen-125 (CA-125) as a tumor marker for malignant germ cell tumors (MGCT) of the ovary was investigated and compared with the other recognized tumor markers (human chorionic gonadotrophin (hCG), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA)) and lactate dehydrogenase (LDH) isoenzymes. In the 10 months following June 1984, 4 new cases with MGCT and 1 patient with active disease on treatment were evaluated. In all cases prior to planned surgery the levels of CA-125 were significantly elevated. The serum values ranged from 154 to 617 U/ml (normal < 20 U/ml). In 1 case (pure dysgerminoma) CA-125 was the only tumor marker. In 3 patients (2 mixed germ cell tumors and 1 immature teratoma) serum LDH (LD 1, 2, and 3) was elevated, and AFP was elevated in 1 of these. In the fifth case (mixed germ cell tumor), on treatment, serum AFP was used to monitor the disease. Four patients underwent cytoreductive surgery followed by combination chemotherapy. The changes in the serum levels of CA-125 paralleled those of the other tumor markers while on therapy. In our experience CA-125 is an invaluable indicator of the clinical status of the patient and could be a new tumor marker in patients with MGCT.

AB - The value of cancer antigen-125 (CA-125) as a tumor marker for malignant germ cell tumors (MGCT) of the ovary was investigated and compared with the other recognized tumor markers (human chorionic gonadotrophin (hCG), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA)) and lactate dehydrogenase (LDH) isoenzymes. In the 10 months following June 1984, 4 new cases with MGCT and 1 patient with active disease on treatment were evaluated. In all cases prior to planned surgery the levels of CA-125 were significantly elevated. The serum values ranged from 154 to 617 U/ml (normal < 20 U/ml). In 1 case (pure dysgerminoma) CA-125 was the only tumor marker. In 3 patients (2 mixed germ cell tumors and 1 immature teratoma) serum LDH (LD 1, 2, and 3) was elevated, and AFP was elevated in 1 of these. In the fifth case (mixed germ cell tumor), on treatment, serum AFP was used to monitor the disease. Four patients underwent cytoreductive surgery followed by combination chemotherapy. The changes in the serum levels of CA-125 paralleled those of the other tumor markers while on therapy. In our experience CA-125 is an invaluable indicator of the clinical status of the patient and could be a new tumor marker in patients with MGCT.

UR - http://www.scopus.com/inward/record.url?scp=0022505863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022505863&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(86)90096-X

DO - 10.1016/0090-8258(86)90096-X

M3 - Article

C2 - 2428701

AN - SCOPUS:0022505863

VL - 25

SP - 150

EP - 159

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -